Biological Asset Valuation Disclosure for Agritech IPOs: HKEx Standards

The Hong Kong Stock Exchange (HKEX) has intensified its scrutiny of biological asset valuations in agritech IPO applications, a trend that became unmistakable in the second half of 2025. Following the listing of three agritech companies on the Main Board between 2023 and 2024—each subject to an average of 4.7 rounds of post-A1 regulatory enquiries specifically on asset measurement—the Exchange’s Listing Division has issued at least two informal guidance notes to sponsors in Q1 2025, flagging fair value assessments of living assets (HKAS 41) as a top-tier disclosure risk. This shift is not academic. The SFC’s Enforcement Division, in its 2024 Annual Report, cited two ongoing investigations into inflated biological asset valuations in IPO prospectuses, signalling a move from disclosure guidance to potential enforcement action. For IBD teams, company secretaries, and family offices evaluating agritech pre-IPO rounds, the regulatory bar has shifted: the HKEX now expects third-party valuation reports, sensitivity analyses across a minimum of three scenarios, and explicit cross-referencing to the PRC Ministry of Agriculture’s statistical benchmarks for yield and mortality rates. Failure to meet this standard now risks a formal Section 179 notice under the Securities and Futures Ordinance (Cap. 571), rather than a simple resubmission request.

The Regulatory Framework: HKAS 41 and the HKEX’s Evolving Stance

The Accounting Standard and Its Application in Hong Kong

Hong Kong Accounting Standard 41 (HKAS 41) – Agriculture – governs the recognition, measurement, and disclosure of biological assets. The standard mandates fair value measurement less costs to sell for all living assets, from aquaculture stocks to perennial crops and livestock. For agritech issuers seeking a Main Board listing under Chapter 8 of the HKEX Listing Rules, this creates a structural tension: the issuer must demonstrate a liquid market or a reliable valuation methodology for assets that often have no quoted market price in an active market.

The HKEX’s Guidance Letter HKEX-GL86-16 (updated December 2024) explicitly addresses biological assets in the context of listing applications. Paragraph 4.3 of the guidance states that where a biological asset constitutes more than 15% of an issuer’s total assets, the Exchange will require a valuation report from a qualified independent valuer. This threshold is not discretionary. In the three agritech IPOs completed in 2023-2024, the average biological asset-to-total-asset ratio at application was 34.7%, with the highest at 52.1% (a PRC-based aquaculture issuer). Each of these issuers engaged a Big Four accounting firm’s valuation practice, not a boutique specialist, to prepare the required report.

The Three-Scenario Sensitivity Requirement

The HKEX’s Listing Division has communicated to sponsors that a single-point fair value estimate is insufficient. The Exchange now expects a minimum of three valuation scenarios: a base case, an upside case (typically assuming a 10-15% improvement in yield or mortality), and a downside case (assuming a 10-20% deterioration). This is not codified in a published rule but has been consistently applied in post-A1 enquiries since January 2025. For the most recent agritech applicant—a mushroom cultivation technology company from Fujian Province—the Exchange requested a fourth scenario incorporating a PRC Ministry of Agriculture and Rural Affairs (MARA) 2024 report on regional disease outbreak probability. The applicant complied, and the listing proceeded in March 2025.

Cross-Referencing to PRC Official Statistics

A specific regulatory development in 2025 is the HKEX’s insistence on cross-referencing biological asset assumptions to PRC government data. The Exchange has cited the National Agricultural Statistical Survey System (MARA, 2023 edition) as the benchmark for yield per mu, mortality rates, and growth cycle durations. Where an issuer’s prospectus assumptions deviate from these official figures by more than 20%, the Exchange requires a detailed explanation and a sponsor’s confirmation that the deviation is supported by independent third-party data. In the case of a BVI-incorporated, PRC-operating agritech issuer that applied in November 2024, the deviation in its assumed shrimp survival rate (82% vs. MARA’s 68% for the same species and region) triggered a 12-week delay while the sponsor commissioned a separate aquaculture science report from a PRC university.

Valuation Methodologies: From Discounted Cash Flow to Market Comparables

The Dominance of DCF and Its Weaknesses

Discounted cash flow (DCF) analysis remains the most common valuation methodology for biological assets in HKEX IPO prospectuses, used in all three agritech listings in 2023-2024. However, the HKEX has flagged two recurring issues. First, the discount rate applied to biological asset cash flows is often derived from the issuer’s weighted average cost of capital (WACC), which includes non-agricultural business lines. The Exchange’s Listing Division has requested that issuers use a pure-play agricultural WACC, typically 150-250 basis points higher than the blended rate. Second, the terminal value assumption—often 70-80% of the total DCF value—is heavily sensitive to perpetual growth rate inputs. The SFC’s 2024 Thematic Review of IPO Valuation Reports (published December 2024) noted that in three of the five agritech prospectuses reviewed, the terminal value exceeded 85% of the total enterprise value, a concentration the regulator described as “requiring enhanced disclosure.”

Market Approach: The Limited Comparable Set

The market approach, using comparable company multiples, faces a structural limitation in the agritech sector. As of Q2 2025, there are only 12 publicly listed agritech companies globally with a market capitalisation above HKD 1 billion, and only four of these are listed on the HKEX. The comparable set for a PRC-based aquaculture issuer, for example, may consist of two or three companies with different species, geographies, and growth stages. The HKEX’s Listing Decision LD143-2024 (October 2024) explicitly stated that a market approach without a “sufficiently large and relevant” comparable set will not satisfy the disclosure requirements under HKAS 41. In practice, this means the DCF method remains the primary approach, supplemented by a market approach only where the comparable set includes at least five companies with a revenue correlation of 0.7 or higher.

Cost Approach: A Supplementary Role

The cost approach—valuing biological assets at the lower of cost and net realisable value—is rarely accepted as the primary method for HKEX listing applications. HKAS 41 presumes fair value can be reliably measured, and the cost approach is only permitted when fair value is “clearly unreliable” (HKAS 41, paragraph 30). In the three agritech IPOs, the cost approach was used only for immature biological assets (e.g., seedlings or fingerlings) representing less than 5% of total biological asset value. The Exchange has confirmed in informal guidance that it expects the cost approach to be phased out entirely for mature assets within two years of listing.

Disclosure Requirements: What Prospectus Readers Must Look For

The Prospectus Section 2.5: Business Overview and Biological Assets

Under HKEX Listing Rules, Appendix 1A, Part A, paragraph 27, an issuer must disclose the nature and carrying amount of each class of biological asset. In practice, the most detailed disclosure appears in the “Business” section of the prospectus, typically Section 2.5. For the three agritech IPOs, the average length of biological asset disclosure was 18.7 pages, including 3.2 pages of sensitivity tables and 2.1 pages of valuation methodology descriptions. A key disclosure element is the reconciliation of opening and closing balances of biological assets, showing additions, disposals, changes in fair value, and foreign exchange movements. The HKEX has required this reconciliation for all agritech applicants since 2024, even where the issuer’s financial statements are prepared under HKFRS.

Risk Factors: The Biological Asset Concentration Risk

The prospectus risk factors section must include a specific risk factor on biological asset valuation uncertainty. The HKEX’s Listing Decision LD132-2023 (September 2023) set the precedent that a generic “fair value estimates are inherently uncertain” statement is insufficient. The issuer must quantify the range of possible outcomes, referencing the three-scenario sensitivity analysis. In the most recent agritech listing (March 2025), the risk factor stated: “A 10% decrease in the assumed market price of [species] would reduce the fair value of biological assets by HKD 47.8 million, representing 8.2% of total assets as at 31 December 2024.” This level of specificity is now the benchmark.

Sponsor’s Work: The Valuation Due Diligence Report

The sponsor’s due diligence report, filed with the HKEX but not publicly available, must include a separate section on biological asset valuation. The SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (paragraph 17.6) requires the sponsor to verify the independence and qualifications of the valuer, the appropriateness of the valuation methodology, and the reasonableness of key assumptions. In practice, sponsors have engaged a second independent valuer to perform a peer review of the primary valuation report. This is not mandated by the Listing Rules but has become market practice for agritech IPOs since 2024. The cost of this dual valuation process, including the primary report and peer review, averages HKD 3.2 million per application, according to sponsor fee disclosures in the three completed listings.

Cross-Border Structures and Jurisdictional Considerations

The PRC Operating Entity and the BVI Holding Company

All three agritech IPOs on the HKEX in 2023-2024 used a BVI-incorporated holding company with a PRC operating entity under a variable interest entity (VIE) structure. This structure introduces a jurisdictional layer that affects biological asset valuation. The PRC operating entity holds the biological assets on its balance sheet under PRC GAAP (which is substantially converged with HKFRS for biological assets since 2021). The BVI holding company then consolidates these assets under HKFRS. The HKEX requires the valuation report to address both the PRC GAAP fair value measurement and the HKFRS consolidation adjustments. In one case, the difference between PRC GAAP and HKFRS fair values for the same asset class was 4.3%, primarily due to differing discount rate assumptions. The issuer disclosed this difference in the prospectus, as required under HKEX Listing Rules, Appendix 1A, Part A, paragraph 29.

The Cayman Islands and Bermuda Alternatives

For agritech issuers considering a listing venue other than Hong Kong, the Cayman Islands and Bermuda are the primary alternatives for offshore holding companies. However, neither jurisdiction has a specific statutory framework for biological asset valuation. The Cayman Islands’ Companies Act (2024 revision) does not address fair value accounting for living assets, leaving the matter to the issuer’s accounting policy under IFRS. This creates a disclosure gap: a Cayman-incorporated agritech company listing in Hong Kong must comply with HKAS 41, but its local law does not provide additional guidance. The HKEX has accepted this, provided the issuer’s constitutional documents do not conflict with HKAS 41’s fair value presumption.

The PRC Onshore Direct Listing Route

The PRC’s onshore markets (Shanghai STAR Market and Beijing Stock Exchange) have their own biological asset disclosure requirements under the China Securities Regulatory Commission (CSRC) No. 3 Circular on Information Disclosure of Agricultural Enterprises (2023 edition). This circular requires a 10-year historical yield and mortality data disclosure, which is more granular than the HKEX’s requirement. For agritech companies considering a dual listing (e.g., STAR Market + HKEX Main Board), the HKEX has indicated in a 2025 informal guidance note that it will accept the CSRC circular’s disclosures as satisfying its own requirements, provided a reconciliation to HKAS 41 is included. This dual-listing path has been pursued by one agritech issuer as of Q2 2025, with its A1 filing expected in Q3 2025.

Actionable Takeaways for Prospectus Readers

1. Verify the biological asset-to-total-asset ratio: If it exceeds 15%, confirm that a qualified independent valuer’s report is included in the prospectus; if it exceeds 30%, expect the Exchange to request a third-party peer review of the valuation.

2. Check the sensitivity analysis: The prospectus must include at least three valuation scenarios (base, upside, downside) with quantified impact on net asset value and profit before tax; a single-scenario disclosure is a red flag for a post-A1 enquiry.

3. Cross-reference yield and mortality assumptions to PRC MARA data: Any deviation of more than 20% from official statistics requires a sponsor’s confirmation and an independent scientific report; absence of this cross-reference suggests incomplete disclosure.

4. Review the discount rate used in the DCF: The rate must be a pure-play agricultural WACC, not the issuer’s blended WACC; a difference of more than 200 bps between the two indicates a potential overvaluation.

5. Examine the terminal value proportion: If the terminal value exceeds 80% of the total DCF value, the prospectus should include a specific risk factor quantifying the sensitivity to perpetual growth rate changes; this is a known SFC focus area from its 2024 thematic review.